Tissue Targeted Medicines, Designed In Vivo.

We design tissue-specific medicines in living systems from the start by combining high-throughput in-vivo studies with AI-guided protein design.

The Opportunity

Making Tissue Specificity Tractable through In Vivo Optimization

Knowledge of biological targets and lessons from clinical data have revealed compelling opportunities for therapeutic interventions. Yet, the ability to deliver medicines sufficiently and specifically to the site of action remains one of the greatest challenges in realizing transformational medicines.

Powerful new computational and experimental tools for protein design are held back by the requirement to evaluate molecules in reductionist in vitro assays. But only in vivo data can truly predict how a drug navigates a living system.

Manifold has created an in vivo biologics design platform that empowers creation of medicines that go to specific areas in the body. This is enabled by a proprietary protein barcoding technology, mCodes, that allows tagging and measuring hundreds of candidates in a single animal model; allowing for broad collection of data about the candidate's pharmacokinetics and biodistribution. This rich in vivo data feeds into our AI-enabled protein design platform and allows us to rapidly iterate towards the candidates with the most optimal in vivo profiles.

With the ability to engineer biologics in vivo, Manifold is uniquely enabled to pursue therapeutic opportunities where specific targeting is the challenge to a compelling product profile.

In Vivo Design

Scalable, Parallel In Vivo Discovery with mDesign

Our mDesign™ platform integrates high-throughput in vivo screening with AI-powered protein design to enable the discovery of tissue-targeted therapeutics. Traditional protein engineering relies heavily on iterative optimization in in vitro assays. Manifold Bio has solved the in vivo data generation problem with the invention of mCodes™, a proprietary tagged multiplexing technology to evaluate distribution of over 100 antibody designs at a time in a single animal. The resulting data guides our molecular optimization process directly in living systems. We are using our platform to advance several candidates toward development.

fig 1. the mDesign™ process
Diagram of the mDesign™ process

AI-Guided Protein Design
Powered by In Vivo Data

Our mCodes technology tracks hundreds of drug candidates in parallel animal studies, generating vast amounts of in vivo data. This powers a virtuous AI cycle: the data teaches the AI to design better molecules, which are then tested to generate new data, further improving the AI. The result is a rapidly expanding map of molecular space and a stream of optimized leads, seamlessly connecting AI predictions to real-world performance.

AI-Guided Design (Libraries + Display Technologies)

We pair library and binder design with high-throughput display technologies to rapidly identify novel binders with favorable properties. Each step is guided by a combination of protein language models tuned by our proprietary in vivo data. We have rapidly advanced our ability to design molecules with optimal therapeutic properties and tissue-targeting. These designs are then synthesized for in vivo evaluation.

In-Vivo Data Generation at Scale

We test 100s of AI-designed candidates in vivo simultaneously, revealing how they perform in living systems at an unprecedented scale.

Expanding Proprietary Dataset

The in vivo results, encompassing PK, biodistribution, and functional state data, feed back into our AI models, creating a virtuous cycle of continuous learning and improvement.
Pipeline

Shuttled Therapeutics for Neuromedicine and Beyond

Stylized illustration of a brain

A renaissance has begun in neuroscience with recent clinical data supporting a number of promising targets for therapeutic intervention.

Yet, delivery of diverse modalities across the blood-brain barrier and to specific regions of the brain remains a challenge that limits efficacy and creates burdens on routes of administration.

Manifold has moved quickly using in vivo design to establish a brain shuttling platform and is now building a pipeline of medicines for neurological disorders with immense unmet need.

Indication
In Vivo
Discovery
In Vivo
Optimization
IND-enabling
Alzheimer's Disease
Shuttled Antibody
Parkinson's Disease / MSA
Shuttled Antibody
Multiple Sclerosis
Shuttled Antibody
(Multiple follow-ons)
Shuttled Antibody

Partnerships

We partner around our brain shuttles as well as engineering of tissue and tumor-specificity across multiple modalities, including oligos, ADCs, and immune engagers.

Our team

With deep expertise spanning high-throughput molecular biology, ML-guided protein engineering and drug discovery we're united by a common mission: to create life-changing medicines by unlocking in vivo drug design at scale.

Founders & Leadership

Gleb Kuznetsov, PhD
Co-Founder & CEO
Gleb Kuznetsov, PhD
Pierce Ogden, PhD
Co-Founder & CSO
Pierce Ogden, PhD
Shane Lofgren
Co-Founder & Head of Portfolio Development and Strategy
Shane Lofgren
George Church, PhD
Co-Founder
George Church, PhD
Steve Holtzman
Executive Chairman
Steve Holtzman

Board

Steve Holtzman
Executive Chairman
Gleb Kuznetsov
Co-Founder & CEO
Pierce Ogden
Co-Founder & CSO
Jory Bell
Playground Global
Jeff Huber
Triatomic Capital